Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials
Authors
Keywords
Colon cancer, Stage III, Adjuvant therapy, Risk groups, Microsatellite instability, Deficient mismatch repair, Prognosis, Recurrence
Journal
EUROPEAN JOURNAL OF CANCER
Volume 144, Issue -, Pages 101-112
Publisher
Elsevier BV
Online
2020-12-18
DOI
10.1016/j.ejca.2020.11.016
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients
- (2020) Rosa Schmuck et al. LANGENBECKS ARCHIVES OF SURGERY
- Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.
- (2020) Thierry Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
- (2020) G. Argiles et al. ANNALS OF ONCOLOGY
- LBA-006BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer
- (2019) S Kopetz et al. ANNALS OF ONCOLOGY
- The Association Between Mutations in BRAF and Colorectal Cancer–Specific Survival Depends on Microsatellite Status and Tumor Stage
- (2018) Hendrik Bläker et al. Clinical Gastroenterology and Hepatology
- NCCN Guidelines Insights: Colon Cancer, Version 2.2018
- (2018) Al B. Benson et al. Journal of the National Comprehensive Cancer Network
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- (2018) Axel Grothey et al. NEW ENGLAND JOURNAL OF MEDICINE
- The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
- (2017) Julian Walter Holch et al. EUROPEAN JOURNAL OF CANCER
- PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry
- (2017) Tony El Jabbour et al. JOURNAL OF CLINICAL PATHOLOGY
- Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers
- (2017) Frank A. Sinicrope et al. JAMA Oncology
- Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- (2016) Julien Taieb et al. JNCI-Journal of the National Cancer Institute
- Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- (2016) Julien Taieb et al. JNCI-Journal of the National Cancer Institute
- Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location
- (2016) Kosuke Mima et al. Clinical and Translational Gastroenterology
- Prognostic Effect ofBRAFandKRASMutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab
- (2016) Julien Taieb et al. JAMA Oncology
- Fusobacterium nucleatumin colorectal carcinoma tissue and patient prognosis
- (2015) Kosuke Mima et al. GUT
- Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study
- (2015) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Fusobacterium nucleatumand T Cells in Colorectal Carcinoma
- (2015) Kosuke Mima et al. JAMA Oncology
- BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer
- (2014) Rona Yaeger et al. CANCER
- KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
- (2014) H. H. Yoon et al. CLINICAL CANCER RESEARCH
- Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
- (2014) Julien Taieb et al. LANCET ONCOLOGY
- Sex Differences in Colorectal Cancer Survival: Population-Based Analysis of 164,996 Colorectal Cancer Patients in Germany
- (2013) Ondrej Majek et al. PLoS One
- Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum
- (2012) Mai Yamauchi et al. GUT
- Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer
- (2012) Daniel J. Sargent JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Gender Disparities in Metastatic Colorectal Cancer Survival
- (2009) A. Hendifar et al. CLINICAL CANCER RESEARCH
- Molecular Characterization of MSI-H Colorectal Cancer by MLHI Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation Screening
- (2008) J. N. Poynter et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search